// App-Quantinova.ai

4164 : Hematopoietic Bone Marrow Transplantation (BMT) for Patients with High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using HLA-Haploidentical Related Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined with Immunosuppression Before and After BMT

Researchers

Presenter

  • Paul -Donnell

Principal Investigators

  • Ted A. Gooley

  • Rainer Storb

  • Frederick R. Appelbaum

  • Oliver W. Press

  • John M. Pagel

  • Joseph G Rajendran

  • Darrell R. Fisher

  • Ajay K. Gopal

  • H. Joachim Deeg

  • Andrew Shields

  • Damian J. Green

  • David G. Maloney

  • Brenda M. Sandmaier

Medical Centers

  • Department of Laboratory Medicine, University of Washington, Seattle, WA

  • Dept of Medicine, Univ of Washington, Seattle, WA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Acute lymphoblastic leukemia

  • Graft-versus-host disease

  • Alpha-thalassemia myelodysplasia syndrome

  • Acute myelocytic leukemia

  • Sepsis

Biomarkers

  • Breakpoint Cluster Region

  • Cluster of Differentiation 2AP

  • Hematocrit

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Mycophenolate mofetil

  • CKD-4101

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Mycophenolic acid

  • fludarabine tablet

  • Tacrolimus

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved